8311 Ewing Halsell Dr.
San Antonio, Texas 78229
Cracking cancer’s code: New research identifies novel drug target for acute myeloid leukemia treatment
Despite advances in cancer treatment in recent years, five-year survival rates for acute myeloid leukemia (AML) remain low at just 30% on average, according to the National Cancer Institute. Factors in the development of AML are diverse with many different drivers. A longtime goal for scientists in this field is finding a single drug that can treat all types of AML.
Drug shows promise for treating brain tumors resulting from breast cancer, UT Health San Antonio trial reports
A drug effective in treating breast cancer shows new promise in addressing breast cancer with brain metastases or recurrent glioblastoma, as reported by results of a prospective window-of-opportunity trial at the University of Texas Health Science Center at San Antonio (UT Health San Antonio). The window trial, in which patients agreed to receive a novel […]
Our Cancer Programs
Our Cancer Programs
Gastrointestinal (GI) Cancer Program
Gastrointestinal (GI) Cancer Program
Liver Tumor and Liver Cancer Program
Liver Tumor and Liver Cancer Program
Postbaccalaureate Fellows Program in Cancer Research
Postbaccalaureate Fellows Program in Cancer Research
Diversity in Cancer Research Internship
Diversity in Cancer Research Internship